Research Group on Cardiometabolic Risk and Diabetes
Cardiovascular Area
In terms of scientific activity of the research group during 2022, our group is participating in the development of three competitive and multidisciplinary research projects that include the following aims:
– Project: Immunopharmacological modulation of the systemic inflammation associated to metabolic disorders. Search for new therapeutic targets and synthesis of novel drugs
– Project: Study of new inflammatory and angiogenic mechanisms associated to severe morbid obesity
– Project: Role of the inflammatory processes in metabolic diseases and associated complications
– Project: Evaluation of the efficacy of pharmacogenetics to improve the response to treatment in subjects with insufficiently controlled type 2 diabetes
Coordinator
Coordinator
STAFF
Collaborating Researchers
Ana Palanca PalancaEsther Benito CasadoRaúl Larriba Salinas
Nurse
Pilar Aguilar Santaisabel
Technicians
Administrative assistant
Publications
CCL17 and CCL22 chemokines are upregulated in human obesity and play a role in vascular dysfunction. Hueso L, Marques P, Morant B, Gonzalez-Navarro H, Ortega J, Real J, Sanz M, Piqueras L. Frontiers in Endocrinology. 2023 Apr 12;14:1154158. doi: 10.3389/fendo.2023.1154158. PMID: 37124725
Digestive toxicity in cancer treatments. Bibliographic review. Influence on nutritional status. Alonso Dominguez T, Civera Andres M, Santiago Crespo J, Garcia Malpartida K, Botella Romero F. Endocrinologia, Diabetes y Nutricion. 2023 Feb;70(2):136-150. doi: 10.1016/j.endien.2023.02.004. PMID: 36868926
Excellent results in terms of weight loss and Type 2 Diabetes control are maintained 20 years after Roux-en-Y gastric bypass. Lapena-Rodriguez M, Cassinello-Fernandez N, Alfonso-Ballester R, Marti-Fernandez RM, Civera-Andres M, Ortega-Serrano J. Journal of Gastrointestinal Surgery. 2023 Jul 10. doi: 10.1007/s11605-023-05734-5. PMID: 37430093
How macronutrients and pancreatic enzyme supplements dose variability affect fat, protein and starch absorption in children with cystic fibrosis. Larriba R, Roca M, Masip E, Canada-Martinez A, Ribes-Koninckx C, Calvo-Lerma J. Digestive and Liver Disease. 2023 Apr;55(4):513-518. doi: 10.1016/j.dld.2022.11.006. PMID: 36435715
Adipokines in non-alcoholic fatty liver disease: are we on the road toward new biomarkers and therapeutic targets?. Francisco V, Sanz M, Real J, Marques P, Capuozzo M, Ait Eldjoudi D, Gualillo O. Biology. 2022 Aug 19;11(8):1237. doi: 10.3390/biology11081237. PMID: 36009862
Association of chemokines IP-10/CXCL10 and I-TAC/CXCL11 with insulin resistance and enhance leukocyte endothelial arrest in obesity. Moreno B, Hueso L, Ortega R, Benito E, Martinez Hervas S, Peiro M, Civera M, Sanz MJ, Piqueras L, Real JT. Microvascular Research. 2022 Jan;139:104254. doi: 10.1016/j.mvr.2021.104254. PMID: 34534571
Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Marques P, Domingo E, Rubio A, Martinez-Hervas S, Ascaso JF, Piqueras L, Real JT, Sanz MJ. Biomedicine & Pharmacotherapy. 2022 Jan;145:112460. doi: 10.1016/j.biopha.2021.112460. PMID: 34864314
Comprehensive management of risk factors in peripheral vascular disease. Expert consensus. Barrios V, Beato P, Brotons C, Campuzano R, Merino-Torres J, Mostaza J, Plana N, Rubio J, Comellas M. Revista Clinica Espanola. 2022 Feb;222(2):82-90. doi: 10.1016/j.rceng.2020.11.011. PMID: 34217671
Anthropometric indicators as a tool for diagnosis of obesity and other health risk factors: a literature review. Piqueras P, Ballester A, Dura-Gil J, Martinez-Hervas S, Redon J, Real J. Frontiers in Psychology. 2021 Jul 9;12:631179. doi: 10.3389/fpsyg.2021.631179. PMID: 34305707
Conversations and Reactions Around Severe Hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Ampudia-Blasco F, Artime E, Diaz S, Rubio M, Reviriego J, Mitchell B, Osumili B, Peyrot M, Pokrzywinski R, Spaepen E, Snoek F. Endocrinologia, diabetes y nutrición. 2021 Oct;68(8):557-566. doi: 10.1016/j.endien.2021.11.012. PMID: 33461913
Dissecting abdominal aortic aneurysm is aggravated by genetic inactivation of LIGHT (TNFSF14). Herrero-Cervera A, Espinos-Estevez C, Martin-Vano S, Taberner-Cortes A, Aguilar-Ballester M, Vinue A, Piqueras L, Martinez-Hervas S, Gonzalez-Navarro H. Biomedicines. 2021 Oct 22;9(11):1518. doi: 10.3390/biomedicines9111518. PMID: 34829747
Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI ?27 kg/m2. Danne T, Edelman S, Frias J, Ampudia-Blasco F, Banks P, Jiang W, Davies M, Sawhney S. Diabetes, Obesity & Metabolism. 2021 Mar;23(3):854-860. doi: 10.1111/dom.14271. PMID: 33289297
Chronic kidney disease as a cardiovascular risk factor. Carmena Rodriguez R, Ascaso Gimilio J, Redón Mas J. Journal of Hypertension. 2020 Nov;38(11):2110-2121. doi: 10.1097/HJH.0000000000002506. PMID: 32649622
Clinical and genetic differences between heterozygous familial hypercholesterolemia patients with and without type 2 diabetes. Climent E, Pérez-Calahorra S, Benaiges D, Pintó X, Suárez-Tembra M, Plana N, Sánchez-Hernández RM, Valdivielso P, Ascaso JF, Pedro-Botet J. Revista Espanola de Cardiologia. 2020 Sep;73(9):718-724. doi: 10.1016/j.rec.2019.09.001. PMID: 31672559
Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance. Taberner-Cortes A, Vinue A, Herrero-Cervera A, Aguilar-Ballester M, Real J, Burks D, Martinez-Hervas S, Gonzalez-Navarro H. International Journal of Molecular Sciences. 2020 Dec 3;21(23):9216. doi: 10.3390/ijms21239216. PMID: 33287201
Decreased Urinary Levels of SIRT1 as Non-Invasive Biomarker of Early Renal Damage in Hypertension. Martínez Arroyo O, Ortega Gutiérrez A, Galera Martos M, Solaz Moreno E, Martinez Hervas S, Redón Mas J, Cortés Vergaz R. International Journal of Molecular Sciences. 2020 Sep 2;21(17):6390. doi: 10.3390/ijms21176390. PMID: 32887498
Projects
Title: Identificación de nuevas dianas terapéuticas y mecanismos de la modulación de la inflamación en las enfermedades metabólicas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Herminia González Navarro, Sergio Martínez Hervás
Duration: 2023 – 2025
Total budget: 147.620,00 €
Title: Estudio de nuevos ejes de quimiocinas como potenciales dianas de intervención en la obesidad y la resistencia a la insulina
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Laura Piqueras Ruiz, José Tomas Real Collado
Duration: 2022 – 2024
Total budget: 204.490 €
Title: ImpactT2D: una estrategia genómica para implementar medicina de precisión en la diabetes tipo 2
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Felipe Javier Chaves Martínez
Duration: 2022 – 2025
Total budget: 106.700 €
Title: Evaluación de la eficacia de la farmacogenética para mejorar la respuesta al tratamiento en sujetos con diabetes tipo 2 insuficientemente controlada
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Sergio Martínez Hervás
Duration: 2022 – 2025
Total budget: 267.300 €
Title: Investigación en Enfermedades Inflamatorias
Funding body: Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital
Principal Investigator: Vera Lucía Gomes Francisco
Duration: 2022 – 2024
Total budget: 66.218 €
Title: Una aproximación traslacional desde la clínica a la experimentación animal: Estudio del papel del eje CCL11/CCR3 y la inflamación eosinofílica en la patología cardiovascular asociada a desórdenes metabólicos
Funding body: Conselleria de Educación, Cultura y Deporte
Principal Investigator: Mª Jesús Sanz Ferrando
Duration: 2020 – 2023
Total budget: 211.736 €
Title: Papel de los procesos inflamatorios en las enfermedades metabólicas y en las complicaciones asociadas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Herminia González Navarro, Sergio Martínez Hervás
Duration: 2020 – 2022
Total budget: 159.720 €
Title: Identificación de nuevos mecanismos implicados en la angiogénesis e inflamación en pacientes obesos. Modulación por ligandos de receptores nucleares constitutivos de androstano
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Laura Piqueras Ruiz, José Tomas Real Collado
Duration: 2019 – 2022
Total budget: 173.333 €
Title: Modulación farmacológica del sistema inmune como diana clave en la prevención de la enfermedad cardiovascular asociada a desordenes metabólicos. Síntesis de fármacos novedosos
Funding body: Ministerio de Economía y Competitividad
Principal Investigator: Mª Jesús Sanz Ferrando, Juan F. Ascaso Gimilio
Duration: 2018 – 2021
Total budget: 205.700 €
Title: CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERdem)
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: José Tomás Real Collado
Duration: 2008 –
Total budget: 154.577 €
+ Info
Doctoral candidate: Alabadí Pardiñes, Blanca
Director(s): Real Collado, Jose Tomás; Civera Andrés, Miguel
Date of the defense: 11/11/2022
University: Universitat de València
Title: Effect of SGLT-2 inhibition in abdominal aortic aneurysm development. Role of rora in adipose tissue inflammation associated to obesity
Doctoral candidate: Ortega Herráiz, Rebeca
Director(s): Piqueras Ruiz, Laura; Sanz Ferrando, María Jesús; Real Collado, José Tomás
Date of the defense: 21/02/2022
University: Universitat de València
Title: La ecografía Doppler con flujo en color en el diagnóstico, tratamiento y pronóstico de la enfermedad de Graves-Basedow
Doctoral candidate: Rubio Puchol, Olalla
Director(s): Merchante Alfaro, Agustín Ángel; Martínez Hervás, Sergio
Date of the defense: 25/01/2022
University: Universitat de València
Title: Influencia de la situación postprandial sobre el eje CCL11/CCR3 en sujetos con hipercolesterolemia
Doctoral candidate: Perelló Camacho, Eva
Director(s): Ascaso Gimilio, Juan F; Real Collado, Jose Tomás
Date of the defense: 23/11/2020
University: Universitat de València
Title: Efecto de los parámetros epigenéticos tras dos años de la cirugía bariátrica
Doctoral candidate: Wu Xiong, Ning Yun
Director(s): Ascaso Gimilio, Juan F; Real Collado, Jose Tomás
Date of the defense: 22/09/2020
University: Universitat de València
Title: Identificación de variantes genéticas relacionadas con diabetes mellitus tipo 2 en población española
Doctoral candidate: Lendínez Tortajada, Verónica
Director(s): Chaves Martínez, Felipe Javier; Real Collado, Jose Tomás
Date of the defense: 31/01/2020
University: Universitat de València
Title: Metilación del ADN de adipocitos en sujetos con obesidad mórbida
Doctoral candidate: Martínez Ibáñez, Juncal
Director(s): Real Collado, Jose Tomás; Ascaso Gimilio, Juan F
Date of the defense: 22/07/2019
University: Universitat de València
Title: Lipemia postprandial y regulación génica en la obesidad mórbida
Doctoral candidate: Artero Fullana, Ana
Director(s): Real Collado, Jose Tomás; Ascaso Gimilio, Juan F
Date of the defense: 21/03/2019
University: Universitat de València